Uncertainty Quantification of the Hybrid Method for Particle Field Measurement using Digitial In-line Holography.
Abstract Not Provided
Guildenbecher, Daniel Robert↗
Engineering topics
Jun, Chen
Publications and source records attributed to Jun, Chen.
A Phase I Clinical and Pharmacology Study Using Amifostine as a Radioprotector in Dose-escalated Whole Liver Radiation Therapy
Purpose: Diffuse intrahepatic tumors are difficult to control. Whole-liver radiotherapy has been limited by toxicity, most notably radiation-induced liver disease. Amifostine is a prodrug free-radical scavenger that selectively protects normal tissues and, in a preclinical model of intrahepatic cancer, systemic amifostine reduced normal liver radiation damage without compromising tumor effect. We hypothesized that amifostine would permit escalation of whole-liver radiation dose to potentially control microscopic disease. We also aimed to characterize the pharmacokinetics of amifostine and its active metabolite WR-1065 to optimize timing of radiotherapy. Methods and Materials: We conducted a radiation dose-escalation trial for patients with diffuse, intrahepatic cancer treated with whole-liver radiation and intravenous amifostine. Radiation dose was assigned using the time-to-event continual reassessment method. A companion pharmacokinetic study was performed. Results: Twenty-three patients were treated, with a maximum dose of 40 Gy. Using a logistical regression model, compared with our previously treated patients, amifostine increased liver tolerance by 3.3 {+-} 1.1 Gy (p = 0.007) (approximately 10%) with similar response rates. Peak concentrations of WR-1065 were 25 {mu}M with an elimination half-life of 1.5 h; these levels are consistent with radioprotective effects of amifostine in patients. Conclusion: These findings demonstrate for the first time that amifostine is a normal liver radioprotector. They further suggest that it may be useful to combine amifostine with fractionated or stereotactic body radiation therapy for patients with focal intrahepatic cancer.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Nuclear Data Sheets for A = 44
The experimental data are evaluated for known nuclides of mass number A=44 (Si,P,S,Cl,Ar,K,Ca,Sc,Ti,V, Cr,Mn). Detailed evaluated level properties and related information are presented, including adopted values of level and {gamma}-ray energies, decay data (energies, intensities and placement of radiations), and other spectroscopic data. This work supersedes earlier full evaluations of A=44 published by 1999Ca45 and 1990En08 (also 1998En04 update). No excited states are known in {sup 44}Si, {sup 44}P, {sup 44}Cr, {sup 44}Mn. Only one excited state is known in 44V and its Isobaric Analog State (IAS) has been observed but with the level energy not known. Information for {sup 44}S, {sup 44}Cl and {sup 44}Ar is limited and their radioactive decay schemes seem incomplete in view of large Q values and known excitations much below than allowed by Q values. The {sup 44}Ca, {sup 44}Sc and {sup 44}Ti nuclides remain as the most extensively studied from many different reactions and decays.
73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗